Glaxo Ends Synta Partnership

Xconomy Boston — 

GlaxoSmithKline has pulled out of a collaboration with Lexington, MA-based Synta Pharmaceuticals (NASDAQ: [[ticker:SNTA]) to co-develop elesclomol as a cancer treatment. The drug failed earlier this year in a pivotal clinical trial among patients with melanoma that had spread through the body. Synta is now focusing its resources on other drugs in its portfolio, including one made to block the Hsp90 pathway that’s related to tumor growth.